Similar Articles |
|
The Motley Fool April 11, 2007 Billy Fisher |
A Replacement for Vioxx at Merck? Drug company has new pain medication in the pipeline. If Arcoxia is approved despite the long odds against it, it could payoff over the long run for Merck shareholders. |
The Motley Fool January 25, 2005 Stephen D. Simpson |
Prognosis Good for Merck The pharmaceutical weathered a tough year but should ride out its Vioxx troubles. While strict value investors may be put off, risk-tolerant investors can buy these shares today. |
The Motley Fool October 7, 2004 Brian Gorman |
Pfizer Will Weather the Storm The company will likely come out on top regardless of the outcome of the latest controversies. Pfizer remains a quality choice for long-term investors. |
The Motley Fool September 30, 2004 W. D. Crotty |
Merck Chokes Back Vioxx The $2.3 billion arthritis drug is withdrawn from the market after clinical studies point to dangerous side-effects. Despite the bad news, Merck's big dividend payouts don't appear to be in jeopardy at the moment. |
The Motley Fool January 27, 2004 Jeff Hwang |
Merck in the Balance These are troubled times for Merck. Restructuring charges, Zocor sales woes, and a new distribution program hamper earnings. |
The Motley Fool December 17, 2004 W.D. Crotty |
Painful Pain Drugs Pfizer joins Merck in the COX-2 inhibitor penalty box. Pfizer's stock, has drifted down since the Vioxx news. |
The Motley Fool October 4, 2004 Mathew Emmert |
Got Merck? The pharmaceutical's investors can't seem to catch a break. |
The Motley Fool September 18, 2007 Brian Orelli |
New York Tag-Teams Merck Both the city and state of New York sue Merck over Vioxx payments, alleging the big pharma defrauded Medicaid and other government agencies, by hiding problems related to its painkilling drug. |
The Motley Fool March 1, 2006 Rich Duprey |
Celebrex Doubles Lawsuit Risk A new study says the Pfizer painkiller doubles the risk of a heart attack. Investors, beware. |
The Motley Fool January 26, 2006 Rich Duprey |
Will Acquisitions Patch Merck's Pipeline? The pharmaceutical giant announces a biotech shopping spree. A few key acquisitions that contribute late-stage drugs and significant revenue might be all Merck needs to keep its pipeline open. Investors, take note. |
The Motley Fool December 21, 2006 Brian Lawler |
Dueling Fools: Merck Bull Rebuttal Plenty of cash. Big pipeline. Not to worry. The future can't be predicted, but Merck's history shows its ability to weather even the toughest pharmaceutical-development environments. |
The Motley Fool October 23, 2006 Brian Lawler |
Merck Mints Money The pharmaceutical hangs on, despite ongoing Vioxx woes. Conservative investors may do best to stay away from Merck until a lower share-price opportunity presents itself, now that shares are no longer sporting such a large Vioxx discount. |
The Motley Fool February 23, 2005 Stephen D. Simpson |
Take Two on COX-2 FDA panel recommendations breathe new life into Merck and Pfizer's COX-2 pain medications. Looking ahead, investors should give a good, long look to the drug sector. |
The Motley Fool February 21, 2006 Rick Aristotle Munarriz |
Biggest Disappointment: Merck In the spirit of the Winter Olympics, here are stock challenges from the publication's writers: Merck is rich in cash, tradition, and potholes. |
The Motley Fool April 17, 2007 Brian Lawler |
Merck Raises the Earnings Roof Shares of Merck soar after it raises 2007 earnings guidance. |
The Motley Fool June 3, 2005 Brian Gorman |
Merck's New Innovation Pending FDA approval, the company's experimental shingles vaccine will probably be a steady earner. In the near term, the stock isn't going to see huge gains, but the company is here to stay and will keep innovating. |
The Motley Fool November 23, 2004 W.D Crotty |
5 Drugs to Worry About? The recall of Merck's Vioxx raises concern among investors that there may be other pharmaceutical companies with potential legal exposure. |
Pharmaceutical Executive January 1, 2006 Jeannette Park |
Thought Leader: Q&A with Cheryl Buxton Cheryl Buxton talks about what impact Merck's decision to cut nearly 11 percent of its work force - in hopes of saving $4 billion dollars by 2010 - will have on the company's future. |
The Motley Fool August 26, 2005 Stephen D. Simpson |
Merck Broaches the Obvious Merck will naturally end up settling many Vioxx cases, but the details are far from clear at this point. Investors, take note. |
The Motley Fool June 23, 2005 Stephen D. Simpson |
Dueling Fools: Merck Bear Rebuttal There's a reason why Merck's stock is cheap: weak pipeline, weak prospects. |
The Motley Fool November 4, 2005 Rich Duprey |
Merck Eases Its Pain The pharmaceutical giant wins an important Vioxx trial. And while it's a welcome reprieve for the company, the decision doesn't seem to warrant the enthusiasm with which the market greeted the decision. |
The Motley Fool December 21, 2006 Ryan Fuhrmann |
Dueling Fools: Merck Bear Investors, because of its recent run-up, the risk/reward tradeoff is not very compelling. There are safer, more lucrative ways to invest in the space. |
The Motley Fool August 22, 2005 Stephen D. Simpson |
Vioxx Brings the Pain A jury stings Merck for hefty Vioxx damages, battering shares. |
The Motley Fool April 8, 2005 Charly Travers |
The FDA Hammers Pfizer Regulatory agency orders a billion dollar blockbuster off the market. Should investors care? |
The Motley Fool June 23, 2005 Stephen D. Simpson |
Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist? |
BusinessWeek July 25, 2005 Gene G. Marcial |
Is Merck Rallying After That Nasty Tumble? Although most analysts who track Merck remain bearish on the beleaguered drugmaker, some upbeat investors are buying. Why? It's Vioxx market may have softened, but its new vaccines will rise to the occasion. |
The Motley Fool November 18, 2004 Lawrence Meyers |
Sympathy for Pfizer The market acts like Vioxx, Bextra, and Celebrex are the same drugs. They're not. Investors should change direction. |
The Motley Fool July 23, 2007 Brian Lawler |
Merck Not Hurt Merck repeats another nice quarter of bottom-line growth despite growing concerns about generic competition. |
The Motley Fool January 10, 2012 Sean Williams |
2012 Preview: Merck The biggest question mark facing the pharmaceutical behemoth in 2012 is just how badly it will be affected by losing patent-exclusivity rights on its biggest drug, Singulair. |
BusinessWeek April 21, 2011 Tom Randall |
Merck's Risky Bet on Research CEO Frazier, who made his name fighting drug lawsuits, is investing billions to churn out new medicines. |
The Motley Fool November 8, 2004 Brian Gorman |
Pfizer's Gloom Factor The stock will continue to be depressed, but things will improve if Celebrex's safety is proven. |
The Motley Fool February 22, 2005 Charly Travers |
Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list. |
The Motley Fool December 13, 2005 Rich Duprey |
Merck's Bitter Pill The first federal Vioxx trial ends with a deadlocked jury, but that's not necessarily good news for the drugmaker, or investors. |
The Motley Fool September 7, 2007 Billy Fisher |
Epic Vioxx Victory for Merck Merck scores a major victory in its Vioxx saga in the courtroom as New Jersey's Supreme Court rules against the possibility of a national class action Vioxx lawsuit. Shares react positively. |
The Motley Fool April 7, 2005 Brian Gorman |
Merck Soldiers On The drug company's experimental HPV treatment has significant potential. Investors should not overlook the company's positive developments. |
The Motley Fool June 23, 2005 Rich Smith |
Dueling Fools: Merck Bull It's hard to argue with a price this cheap. With a price-to-free cash flow ratio of less than 11, Merck's a steal. |
The Motley Fool January 31, 2005 Stephen D. Simpson |
Merck Takes Another Body Blow Loss of exclusivity on major osteoporosis drug could take steam out of the recovery process. Investors in Merck just can't catch a break. |
The Motley Fool December 21, 2004 Brian Gorman |
Pfizer Won't Let Go Pfizer is hoping that Celebrex will survive in some form. But the pharmaceutical giant has also determined that the drug should no longer be advertised to consumers. Its shares were pounded again following its revelation that it would pull such ads. |
The Motley Fool September 25, 2006 Brian Lawler |
Merck's Positive Contribution Bad press from Vioxx shouldn't overshadow the company's new offering. Investors, take note. |
The Motley Fool March 9, 2009 Brian Orelli |
Merck-Schering Trumps Pfizer-Wyeth The new Merck deal looks a lot better than a combined Pfizer plus Wyeth. |
The Motley Fool April 10, 2006 Rich Duprey |
Merck Splits the Difference The pharmaceutical wins one, loses one in New Jersey Vioxx trials. Investors should expect to see more losses. |
BusinessWeek November 24, 2010 Tom Randall |
Merck May Have a Cholesterol Winner Merck told doctors at the American Heart Assn. annual meeting that new data showed its drug anacetrapib had reduced bad cholesterol by 40 percent while raising good cholesterol by an unprecedented 138 percent. |
The Motley Fool December 21, 2006 Ryan Fuhrmann |
Dueling Fools: Merck Bear Rebuttal Yes, Merck is a good company, but investors can still do better. |
BusinessWeek March 6, 2006 Amy Barrett |
Merck: Out Of The Ivory Tower Merck's pragmatic strategy includes tweaking the vitamin niacin to make it a blockbuster. |
The Motley Fool February 25, 2004 Brian Gorman |
Merck's Slow and Steady The big pharma's cautious approach could pay off in the industry. |
The Motley Fool May 27, 2005 Stephen D. Simpson |
Once More With Merck Merck has had a busy spring, but are investors any better off? |
The Motley Fool January 31, 2007 Brian Lawler |
Merck Plays the Waiting Game New acquisitions may help the drugmaker weather tough times. Investors, take note. |
Chemistry World March 13, 2007 |
Vioxx Trial Blow for Merck A jury has awarded $47.5 million to an Idaho man after finding that the anti-inflammatory drug Vioxx, made by Merck and Co., Inc., contributed to his heart attack. |
The Motley Fool May 16, 2005 Ellen Dowling |
Merck Minds Its Manners The drug giant's handbook for its salespeople has Congress offended. Whether the committee thinks its salespeople are charismatic or just plain con artists, Merck's actions will eventually speak louder than its words for patient investors. |
The Motley Fool December 21, 2006 Brian Lawler |
Dueling Fools: Merck Bull What you are getting with Merck is one of the best-managed pharmas out there that will be experiencing solid double-digit earnings growth in the not-too-distant future with a smart dividend payout. |